QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ASND

QT68Ascendis Pharma A/S
NASDAQ·Healthcare·Biotechnology·DK
Latest market price
230.83
-0.32-0.14%
OverviewShort InterestFilings
ASNDQT68Ascendis Pharma A/S·NASDAQ
OverviewShort InterestFilings
230.83-0.14%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E24.55EPS (ttm)
8.87
Insider Own0.01%
Shs Outstand62.11M
Perf Week7.06%
Market Cap14.36BForward P/E21.14EPS next Y10.92Insider Trans-0.03%Shs Float-Perf Month-3.00%
Enterprise Value14.73BPEG0.05EPS next Q1.29Inst Own-Short Float-Perf Quarter3.13%
Income584.53MP/S14.44EPS this Y74.48%Inst Trans-Short Ratio-Perf Half Y8.83%
Sales994.74MP/B25.46EPS next Y-29.45%ROA25.26%Short Interest-Perf YTD8.25%
Book/sh9.10P/C215.82EPS next 5Y11.18%ROE-5641.90%52W High250.74 -7.94%Perf Year33.50%
Cash/sh10.67P/FCF297.46EPS past 3/5Y-ROIC1.51%52W Low160.86 43.50%Perf 3Y-
Dividend Est.-EV/EBITDA1038.74Sales past 3/5Y143.54% 149.92%Gross Margin88.17%Volatility2.48% 2.60%Perf 5Y-
Dividend TTM-EV/Sales14.81EPS Y/Y TTM65.75%Oper. Margin-0.80%ATR (14)8.90Perf 10Y-
Dividend Ex-Date-Quick Ratio0.72Sales Y/Y TTM156.23%Profit Margin58.40%RSI (14)54.44Recom2.00
Dividend Gr. 3/5Y-Current Ratio1.00EPS Q/Q119.28%SMA202.79%Beta0.33Target Price267.50
Payout0.00%Debt/Eq1.84Sales Q/Q176.42%SMA50-0.40%Rel Volume1.27Prev Close231.15
Employees1,017LT Debt/Eq-2.37EarningsAug 06SMA2005.97%Avg Volume701.41KPrice230.83
IPO DateJan 28, 2015Option/ShortYes / YesEPS/Sales Surpr.70.58% -7.77%Net Debt/EBITDA26.21Volume891,706Change-0.14%
Analyst Ratings
DateActionAnalystRatingTarget
May-15-26ReiteratedEvercore ISI$324 → $329
May-11-26ReiteratedBarclaysOverweight$342 → $345
May-08-26ReiteratedWells FargoOverweight$330 → $326
Mar-05-26ReiteratedJefferiesBuy$196 → $262
Mar-04-26ReiteratedStifel NicolausBuy$325 → $332
Mar-02-26ReiteratedWolfe Research$260
Mar-02-26ReiteratedCantor FitzgeraldOverweight$254 → $300
Mar-02-26ReiteratedEvercore ISI$205 → $324
Mar-02-26ReiteratedGoldman SachsBuy$200 → $255
Feb-12-26ReiteratedStifel NicolausBuy$256 → $325
Latest News
Jun-15-26
Jun-15-2603:13AM
Reported Saturday, Ascendis Pharma's TransCon PTH Achieves 86% Response Rate And 100% Independence From Active Vitamin D Through Week 182 In Phase 3 PaTHway Trial Adults With HypoparathyroidismBenzinga
02:00AM
Ascendis Pharma A/S (ASND) Presents at Endocrine Society's Annual Meeting (ENDO 2026) - SlideshowSeekingAlpha
Jun-12-26
Jun-12-2612:29PM
Why Is Ascendis Pharma Stock Gaining Friday?Benzinga
09:55AM
Touchstone Mid Cap Growth Fund Q1 2026 Portfolio ReviewSeekingAlpha
Jun-11-26
Jun-11-2604:02PM
Ascendis Pharma A/S Data From Phase 2 PaTH Forward Study Of TransCon PTH Demonstrates Sustained Efficacy, Safety In Participants With HypoparathyroidismBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue1,007780393
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A11911648
Gross Profit889664346
Selling, General and Administrative Excl. Other577492308
Research and Development314320332
Other Operating Expense407
Operating Income-6-148-302
Interest Expense2118771
Unusual Expense
———
Non-Operating Income (Expense)0-531
Net Income Before Taxes-195-230-404
Income Taxes-790175
Consolidated Net Income595-247-409
Net Income From Continuing Operations595-247-409
Net Income595-247-409
EPS (Recurring)9.62-4.08-7.06
EPS (Basic, Before Extraordinaries)9.62-4.08-7.06
EPS (Diluted)8.87-4.08-7.06
EBITDA15-124-314
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
26.02——
Price To Sales Ratio14.2116.68—
Gross Margin88.2885.1388.04
Operating Margin-0.60-18.97-76.84
Net Margin59.09-31.67-104.07
Shares Outstanding626158
Market Capitalization14,31113,008—
Operating Lease Expense
———
Insider Trading Volume
$259.05$245.74$232.44$219.13$205.82● Close Price0.00M1.16M2.32M3.48M4.64MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
SMITH SCOTT THOMASEVP & Chief Financial OfficerJun 02 '26Buy219.0010021,9004,367Jun 02 12:00 AM
BIENAIME JEAN JACQUESDirectorMay 29 '26Buy223.12500111,562900Jun 01 12:00 AM
SMITH SCOTT THOMASEVP & Chief Financial OfficerMay 29 '26Buy223.3225055,8304,267Jun 01 12:00 AM
BIENAIME JEAN JACQUESDirectorMay 26 '26Buy237.8040095,121400May 27 12:00 AM
JENSEN FLEMMING STEENSee RemarksMay 11 '26Sale238.4919,4604,641,0210May 12 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR